Overview:

uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

Upcoming Webcast:

February 14-15, 2018
LEERINK Partners 7th Annual Global Healthcare Conference

Click here to view webcast

Webcast Archive:

November 29, 2017
Evercore ISI Biopharma Catalyst/ Deep Dive Conference
Wednesday, November 29, 2017
3:05 p.m. EST / 21:05 CET
Click here to view webcast 

 
October 19, 2017
Hemophilia B Gene Therapy Program Update

Thursday, October 19, 2017
08:30 a.m. EDT/ 14:30 CET
Click here to view the recording of the webcast 
 

 September 6-7, 2017
Citi's 12th Annual Biotech Conference

Thursday, September 7, 2017
11:00 a.m. EDT/17:00 CET
Click here to view webcast

 Upcoming Events:

SunTrust 2018 Orphan Drug Day - New York City
February 13, 2018

LEERINK Partners 7th Annual Global Healthcare Conference - NYC
February 14 - 15, 2018

CHDI: 13th Annual HD Therapeutics Conference - Palm Springs, CA
February 26 - March 1, 2018

ISBiotech 8th Spring Meeting - Norfolk, VA
March 3 - 5, 2018